Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18880054 | 0.95 | DPP7 (0.36) | SIRT6SIRT1FOLH1DPP8DPP9 | |
| SCHEMBL22215611 | 0.87 | GABRR1 (0.39) | DPP8DPP9DPP7 | |
| SCHEMBL24453626 | 0.82 | FURIN (0.41) | SIRT6SIRT1FOLH1DPP8DPP9 | |
| SCHEMBL3727817 | 0.81 | FOLH1 (0.53) | FOLH1CPB2GSRSLC6A5RNPEP | |
| SCHEMBL20978516 | 0.81 | SIRT6 (0.42) | SIRT6SIRT1FOLH1DPP8DPP9 | |
| SCHEMBL209237 | 0.81 | FOLH1 (0.53) | FOLH1CPB2GSRSLC6A5RNPEP | |
| SCHEMBL1413149 | 0.81 | FOLH1 (0.53) | FOLH1CPB2GSRSLC6A5RNPEP | |
| SCHEMBL14878853 | 0.81 | SIRT6 (0.42) | SIRT6SIRT1FOLH1DPP8DPP9 | |
| SCHEMBL20234602 | 0.81 | BLM (0.37) | — | |
| SCHEMBL13707922 | 0.81 | FOLH1 (0.41) | SIRT6SIRT1FOLH1CPB2GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112902-A2 | MELANOCORTIN AND GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20210121585-A1 | PSMA targeted radiotherapy medicine and preparation method thereof | LI MING HSIN (TW) | 2021-04-29 | — | — | US | disclosed |
| US-20120322725-A1 | GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322725-A1 | GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY | GLP1R, GIPR, GCG | SIRT6 1846/4885SIRT1 1164/4885FOLH1 348/4885 |
| US-20210121585-A1 | PSMA targeted radiotherapy medicine and preparation method thereof | FOLH1, KLK3, PSMA1 | SIRT6 2240/4885SIRT1 2332/4885FOLH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.